AC Immune Ltd Asset Resilience Ratio
AC Immune Ltd asset resilience ratio. AC Immune Ltd (ACIU) has an Asset Resilience Ratio of 40.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACIU cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of AC Immune Ltd (2014–2025)
Asset resilience ratio of AC Immune Ltd from 2014 to 2025. This chart shows how AC Immune Ltd's Asset Resilience Ratio has changed over time. Read AC Immune Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down AC Immune Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACIU asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.63 Million | 40.48% |
| Total Liquid Assets | $55.63 Million | 40.48% |
Asset Resilience Insights
- Very High Liquidity: AC Immune Ltd maintains exceptional liquid asset reserves at 40.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AC Immune Ltd Industry Peers by Asset Resilience Ratio
Compare AC Immune Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
AC Immune Ltd Asset Resilience Ratio by Year (2014–2025)
AC Immune Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for AC Immune Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.89% | $64.69 Million | $154.43 Million | -14.07pp |
| 2024-12-31 | 55.96% | $129.21 Million | $230.91 Million | +42.53pp |
| 2023-12-31 | 13.43% | $24.55 Million | $182.81 Million | -35.51pp |
| 2022-12-31 | 48.94% | $91.00 Million | $185.94 Million | +4.57pp |
| 2021-12-31 | 44.37% | $116.00 Million | $261.44 Million | +17.14pp |
| 2020-12-31 | 27.23% | $65.00 Million | $238.74 Million | -4.52pp |
| 2019-12-31 | 31.75% | $95.00 Million | $299.25 Million | +16.48pp |
| 2018-12-31 | 15.26% | $30.00 Million | $196.56 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $132.01 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $156.10 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $79.93 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $30.30 Million | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more